DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

LaunchTrends: Tecfidera (BG-12) (Multiple Sclerosis) (Wave 3) US 2013

BioTrends Research Group is pleased to announce a new syndicated report series, LaunchTrends®: Tecfidera, in 2013. This four-wave primary research study will follow the launch of Tecfidera by Biogen Idec. Waves 1 through 4 track the introduction of Tecfidera based on data collected at one month, three months, six months and one year post-Tecfidera launch.
LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from pre-launch through one year post-launch. These report series provide information on how new products fit into the treatment algorithm, impact current therapies, and change market dynamics. They provide information on awareness, familiarity, and perceived clinical advantages and disadvantages of new products. And, they capture the promotional messages and activities of key market players, as well as counter-detailing by competitors.

Questions Answered in This Report:

  • Measure awareness of and familiarity with Tecfidera among neurologists

  • Understand the perceived clinical advantages and disadvantages of Tecfidera compared to other marketed agents used in treating MS

  • Understand where Tecfidera is expected to fit in the treatment algorithm for MS patients

  • Track the trial, adoption, and prescribing trends of Tecfidera including anticipated future trends for the treatment of MS

  • Collect information on the promotional messages and activities being employed by Biogen Idec


Sample Frame & Methodology:

Waves 1 through 3 will include responses from a random sample of ~75 neurologists unique to each wave; Wave 4 may include a subset of previous respondents for a total of ~100 neurologists

A qualitative follow up arm includes telephone interviews conducted with a sub-set of ~15 survey respondents

To qualify, respondents must meet the following criteria:

- In practice between 2 and 35 years

- Minimum of 20 patients with multiple sclerosis under management

- Treat at least some of their RR-MS patients with DMT therapy

- More than 75% of time spent in clinical practice


Final report in PowerPoint format (from each wave)

Complete set of frequency tables, summary statistics, and cross tabulations (each wave) can be provided upon request

Copies of telephone interviews (as audio files; blinded) can be provided upon request

Proprietary question slide deck and frequency tables

Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions

Product Coverage:

Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tecfidera, Tysabri

Related 2013 Reports:

TreatmentTrends®: Multiple Sclerosis (US)

TreatmentTrends®: Multiple Sclerosis (EU)

LaunchTrends®: Aubagio (US)

LaunchTrends®: Lemtrada (US)

DecisionBase®: Multiple Sclerosis-Chronic Progressive

DecisionBase®: Multiple Sclerosis- Relapsing Remitting

PatientBase®: Multiple Sclerosis in Mexico

PatientBase®: Multiple Sclerosis in Turkey

PatientBase®: Multiple Sclerosis in South Korea

Treatment Algorithms®: Multiple Sclerosis

Pharmacor®: Multiple Sclerosis

Physician and Payer Forum®: Multiple Sclerosis